This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Dr John Crown: differences in the 4- and 5-year outcomes from the NATALEE trial
Indications:1
KISQALI® (ribociclib), in combination with an aromatase inhibitor (AI), is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC) at high risk of recurrence (see section 5.1 of the SmPC for selection criteria).
In pre/perimenopausal women, or in men, the AI should be combined with a luteinising hormone-releasing hormone (LHRH) agonist
KISQALI is not recommended to be used in combination with tamoxifen.
For information on the safety profile of KISQALI in eBC, click here.
Please consult your local Summary of Product Characteristics for the full KISQALI safety and tolerability profile.
Click the play button below to watch the video from Dr John Crown
Join Dr John Crown as he delves deeper into the differences in outcomes reported between the pre-specified 4- and 5-year analyses from NATALEE in patients with HR+/HER2– eBC.
VIDEO
AI, aromatase inhibitor; eBC, early breast cancer; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; SmPC, summary of product characteristics.
Reference
KISQALI® (ribociclib) Summary of Product Characteristics.
UK | November 2025 | FA-11547249
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.